Drug Profile
Tuberculosis vaccine - Vaxil Biotherapeutics
Alternative Names: MTbuVax - Vaxil BioTherapeuticsLatest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator Vaxil BioTherapeutics
- Class Antituberculars; Peptide vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 24 Mar 2023 Preclinical development is ongoing (Prevention) in Israel and USA (Vaxil Biotherapeutics pipeline, March 2023)
- 24 Mar 2023 Preclinical development is ongoing in USA and Israel (Vaxil Biotherapeutics pipeline, March 2023)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Tuberculosis in Israel